secwatch.observer — SEC 8-K summary
======================================

Issuer:     Petros Pharmaceuticals, Inc. (PTPI)
CIK:        0001815903
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0001104659-22-090711
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Petros Pharmaceuticals reports Q2 net sales of $4.2M, first positive adjusted EBITDA of $0.2M
--------------------------------------------------------------------------------

- Q2 net sales of $4.2M, up 68% from $2.5M in Q2 2021; net loss narrowed to $1.8M from $2.1M.
- First positive adjusted EBITDA of $0.2M, compared to negative $2.0M in prior-year period.
- Prescription Medicines segment (STENDRA) sales up 102% YoY to $3.3M; gross margin stable at 84%.
- Cash balance $13.3M as of June 30, 2022, down from $17.7M at March 31, 2022.
- Announced positive OTC label comprehension study for STENDRA and pursuit of 505(b)(2) pathway for H-100 for Peyronie's disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815903/000110465922090711/0001104659-22-090711-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815903/000110465922090711/tm2223325d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-090711

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer